Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyto-KIK: Nivolumab and Cabozantinib with Cytoreductive Nephrectomy in Kidney Cancer
NCT04322955Phase 2Active, not recruiting
- Start
- Jun 2020
- Primary completion
- May 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, cabozantinib in renal cell carcinoma (RCC). Started Jun 2020; status: active, not recruiting.
02
Drugs
nivolumabcabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04322955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04322955.